Research of anti-tuberculosis drugs’  hepatotoxicity

Abstract

Abstract: Hepatotoxicity is one of the side effects of rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride, and it was particularly more serious in antituberculosis drugs combination. This review summarized the pathogenic mechanism and risk factors of hepatotoxicity caused by anti-tuberculosis drugs, and emphasized the importance of clinical monitor of hepatotoxicity. The occurrence of hepatotoxicity is related to the factors such as age, gender, nutrition status, alcohol, slow acetylation genotype and hepatitis B carriers. The administration and monitor of anti-tuberculosis therapy should be strengthened, so that the hepatotoxicity induced by drugs can be controlled.

Key words: Antitubercular agents, Hepatitis, chronic, drug-induced

JIA Zhong，WU Jing，MA Jian-jun，LIANG Yun，LIU Yuan，WANG Xing-gang. Research of anti-tuberculosis drugs’ hepatotoxicity[J]. Chinese Journal of Antituberculosis, 2013, 35(6): 468-471.

References

［1］World Health Organization. Global tuberculosis control 2010. Geneva：World Health Organization, 2011.
［2］Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol, 2004, 4(2): 167-170.
［3］Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol, 2010,105(11):2396-2404.
［4］Steele MA, Burk RF, Des Prez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 1991, 99(2): 465-471.
［5］Awodele O, Akintonwa A, Osunkalu VO. Modulatory activity of antioxidants against the toxicity of rifampicin in vivo. Rev Inst Med Trop Sao Paulo, 2010, 52(1): 43-46.
［6］Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol, 2005, 20(11): 1745-1752.
［7］Fernández-Villar A,Sopea B,Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis, 2004, 8(12): 1499-1505.
［8］杨慧媛, 宋育林, 许建明,等. 抗结核药物肝毒性研究现状及其存在的问题. 安徽医药, 2008, 12(4): 289-292.
［9］李双初, 何丙生, 代秀萍, 等. 2H₃R₃E₃Z₃/4H₃R₃方案引起的药物性肝损害及其对抗结核效果的影响. 中国防痨杂志, 2008, 30 (1): 11-14.
［10］李键, 王修齐, 杨桂仙,等. 药源性消化系统疾病. 北京:科学出版社, 2001: 265-267.
［11］赵凤芹. 抗结核药物诱导肝损伤的评价. 国外医学呼吸系统分册, 2003, 23 (6): 322-324.
［12］Saukkonen JJ,Cohn DL,Jasmer RM, et al. An official ATS statement: heap-totoxicity of antituberculosis therapy. Am J Respir Crit Care Med, 2006, 174（8）: 935-952.
［13］Harada Y, Kawakami K, Koyama K, et al. Case of fatal liver failure due to anti-tuberculous therapy. Kekkaku, 2007,82(9):705-709.
［14］Van Hest R,Baars H,Kik S, et al. Hepatotoxicity of rifamp in pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis, 2004, 39(4): 488-496.
［15］Centers for Disease Control and Prevention(CDC). Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep, 2001, 50(34): 733-735.
［16］方毅敏, 陈志成, 潘四珍. 异烟肼利福平吡嗪酰胺对结核病患者肝功能的影响. 实用医学杂志, 1997, 13（9）: 609-610.
［17］Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J, 1996, 9(10): 2026-2030.
［18］Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology, 1990, 98 (2): 502-504.
［19］Yew WW, Leung CC. Antituberculosis drugs and hepatotoxi-city. Respirology, 2006, 11(6): 699-707.
［20］Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators, possible relation to hydrazine metabolities. Clin Pharmacol Ther, 1975, 18(1): 70-79.
［21］Huang YS, Chem HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 2002, 35(4): 883-889.
［22］Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol, 2003, 41 (11): 1226-1232.
［23］Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother, 2004, 38(6): 1074-1079.
［24］Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003, 37(4): 924-930.
［25］Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferaseM1 ‘null’ mutation. J Gastroenterol Hepatol, 2001,16(9): 1033-1037.
［26］Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti tuberculosis treatment. Am J Respir Crit Care Med, 2002, 166(7): 916-919.
［27］Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother, 2001, 45 (2): 382-392.
［28］Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther, 2001, 299(3): 849-857.
［29］Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest, 1994, 105(2): 408-411.
［30］Thummel KE, Lee CA, Kunze KL, et al. Oxidation of ace-taminophen to N-acetyl-p-aminobenzoquinoneimine by human CYP3A4. Biochem Pharmacol, 1993, 45(8): 1563-1569.
［31］Chamorro JG, Castagnino JP, Musella RM, et al. Sex, ethnicity and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol, 2013, 28(2):323-328.
［32］Mansukhani S, Shah I. Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy. Ann Hepatol, 2012, 11(1):96-99.
［33］Lima Mde F,Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica, 2012, 28(4):698-708.
［34］Marzuki OA, Fauzi AR, Ayoub S, et al. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med, 2008, 49(9): 688-693.
［35］Sukhanov DS, Okovity SV, Demidik SN, et al. Relationship between the endogenous interferon IFN-gamma level and risk of hepatotoxic liver damage in tuberculosis patients. Eksp Klin Farmakol, 2012, 75(6):40-43.
［36］Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis, 1996, 77(4): 335-340.
［37］Shang P,Xia Y,Liu F,et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One, 2011,6(7):e21836.
［38］Wu S,Xia Y,Lv X, et al. Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China. BMC Public Health, 2012, 12:454.

[1]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[2]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
[3]	Shi Lulu, Jing Hui, Liang Min, Li Xuezheng. Analysis of clinical results of blood concentration detection of antituberculosis drugs by liquid chromatography-tandem mass spectrometry [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 886-891.
[4]	Duan Shujuan, Wang Wei, Pang Yu, Li Ling. Research progress on the regulation of host anti-tuberculosis effect by tyrosine kinase inhibitors [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 584-589.
[5]	Shi Chunjing, Liu Xing, Li Longfen, Li Wenming, Zhang Huajie, Wang Ge, Zeng Haiyan, Liu Li, Shen Lingjun. Research progress on the effects of bedaquiline,delamanid and pretomanid on liver function in the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1560-1565.
[6]	Jiayinati Jingesi, Wang Xinqi, Liu Nianqiang, Wang Senlu, Yipaer Aihaiti, Feng Jianyu, Huang Tao, Kedieryekezi Wufuer. Analysis of treatment completeness and its influencing factors of preventive treatment among 387 latent tuberculosis infection cases [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1496-1503.
[7]	Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
[8]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University. Expert consensus on clinical monitoring and management of QTc interval prolongation caused by anti-tuberculous drugs [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 8-17.
[9]	Wang Honghong, Guo Shaochen, Zhou Wenqiang, Liu Zhongquan, Zhu Hui, Lu Yu. Influence of linezolid blood concentration on hematological toxicity in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 165-171.
[10]	Chen Fang, Zhang Xiaofo, Zhou Haiyi, Zhang Feng, Wang Manzhi. Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 45-51.
[11]	LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
[12]	LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong. Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659.
[13]	NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui. Research progress on pharmacokinetics and drug interaction of bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719.
[14]	XUE Yu, ZHANG Jing, NIE Wen-juan. The efficacy and safety of regimen containing bedaquiline in the treatment of elderly drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 582-586.
[15]	LIANG Li, ZOU Li-ping, XIE Fang-hui, CHEN Qing, WU Gui-hui. Three cases of anti-tuberculosis therapy-associated acute liver failure in tuberculosis children and literature review [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 343-348.

Research of anti-tuberculosis drugs’ hepatotoxicity

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments